Dipeptidyl peptidase-4 inhibitor use is associated with a lower erythrocyte sedimentation rate in patients with remitting seronegative symmetrical synovitis with pitting oedema and pre-existing diabetes mellitus-Reference-Cited by-同舟云学术

Dipeptidyl peptidase-4 inhibitor use is associated with a lower erythrocyte sedimentation rate in patients with remitting seronegative symmetrical synovitis with pitting oedema and pre-existing diabetes mellitus

Published:2021-08-12 Issue: Volume: Page:
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:

Author:

Horai Yoshiro¹²^ORCID,Shimizu Toshimasa³⁴,Okada Akitomo⁵,Tokumitsu Junichi⁶,Ikeoka Toshiyuki⁶,Kuriya Genpei⁶⁷,Iwanaga Nozomi¹,Izumi Yasumori⁸,Origuchi Tomoki⁹,Kawakami Atsushi³

Affiliation:

1. Department of Rheumatology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Omura, Japan

2. Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Nagasaki, Omura, Japan

3. Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

4. Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan

5. Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan

6. Department of Endocrinology and Metabolism, National Hospital Organization Nagasaki Medical Center, Nagasaki, Omura, Japan

7. Diabetes Center, Sasebo Chuo Hospital, Nagasaki, Sasebo, Japan

8. Department of General Internal Medicine, National Hospital Organization Nagasaki Medical Center, Nagasaki, Omura, Japan

9. Unit of Translational Medicine, Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://academic.oup.com/mr/advance-article-pdf/doi/10.1093/mr/roab036/41926879/roab036.pdf

Reference18 articles.

1. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome;McCarty;JAMA,1985

2. RS3PE: clinical and research development;Li;Curr Rheumatol Rep,2015

3. Remitting seronegative symmetrical synovitis with pitting edema syndrome in individuals with type 2 diabetes mellitus or impaired glucose tolerance;Oyama;Diabetes Res Clin Pract,2015

4. Novel development of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome due to insulin therapy;Mainali;Am J Case Rep,2014

5. RS3PE in association with dipeptidyl peptidase-4 inhibitor: report of two cases;Yamauchi;Diabetes Care,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Common Comorbidities in Patients with Remitting Seronegative and Symmetrical Synovitis with Pitting Edema (RS3PE);Southern Medical Journal;2024-05

2. Development of Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome with Pembrolizumab for Lung Squamous Cell Carcinoma: A Case Report;Internal Medicine;2024

3. Clinical features of polymyalgia rheumatica patients in Japan: Analysis of real-world data from 2015 to 2020;Modern Rheumatology;2023-03-06

4. Clinical analysis of gender and pre-existing diabetes mellitus in patients with polymyalgia rheumatica: A retrospective study in a Japanese population;Modern Rheumatology;2022-02-03